步长制药(603858.SH)拟注销控股子公司长沙众测生物、湖南众测生物

Core Viewpoint - The company plans to optimize resource allocation and reduce management costs by proposing the cancellation of its subsidiaries, Changsha Zhongce Biotechnology Co., Ltd. and Hunan Zhongce Biotechnology Co., Ltd. [1] Group 1 - The company held its 31st meeting of the 5th Board of Directors on September 4, 2025, where the proposal for the cancellation of the subsidiaries was approved [1] - The cancellation of the subsidiaries is not expected to have a substantial impact on the company's consolidated financial statements [1] - The overall business development and profitability of the company will remain unaffected by this cancellation [1]